Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy

• Главные авторы: Si-Heng Zhang (Автор), Ling-Long Peng (Автор), Yi-Fei Chen (Автор), Yan Xu (Автор), Vahid Moradi (Автор)
• Формат: ‌
• Опубликовано: BMC, 2024-11-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Since chimeric antigen receptor T (CAR-T) cells were introduced three decades ago, the treatment using these cells has led to outstanding outcomes, and at the moment, CAR-T cell therapy is a well-established mainstay for treating CD19 + malignancies and multiple myeloma. Despite the astonis...